Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Squamous Cell Carcinoma of Head and Neck 2Head and Neck Neoplasms 2Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Cisplatin 139pembrolizumab 88Carboplatin 73Radiotherapy 71Cetuximab 69Docetaxel 58Paclitaxel 52Radiotherapy, Intensity-Modulated 43Fluorouracil 43Nivolumab 32Surgical Procedures, Operative 18Albumin-Bound Paclitaxel 15130-nm albumin-bound paclitaxel 15Radiation 14Drug Therapy 14tislelizumab 13Taxes 13durvalumab 12Magnetic Resonance Spectroscopy 12toripalimab 11camrelizumab 11Platinum 11Chemoradiotherapy 11Biopsy 11cemiplimab 10Radiosurgery 10Erlotinib Hydrochloride 10Capecitabine 10Specimen Handling 9Neoadjuvant Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Squamous Cell Carcinoma of Head and Neck × ALX148 × Clear all
NCT04675333 2025-08-03

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

ALX Oncology Inc.

Phase 2 Active not recruiting
172 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04675294 2025-08-01

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

ALX Oncology Inc.

Phase 2 Active not recruiting
189 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡